Med·Investment | News: Medical Device Investment Events (2024.08.03–2024.08.16)

1. Sirrem, a Chinese-produced soft rehabilitation robot, has completed a Pre-A round of financing worth tens of millions of yuan, accelerating the implementation of full-cycle, full-scenario rehabilitation solutions.

To meet the rehabilitation needs of patients with limb dysfunction caused by neurological injuries such as stroke, hand trauma, spinal cord injury, and burns, Sirrem has independently developed an innovative rehabilitation product — a soft robotic hand rehabilitation device. This product integrates advanced technologies like passive rehabilitation, master-slave mirror rehabilitation, and motor imagery rehabilitation based on brain-computer interface (BCI). It can alleviate finger joint edema and stiffness, enhance hand muscle strength, promote cerebral nerve recovery, and help patients make the most of the "golden period" for rehabilitation.

Sirrem's core competitiveness lies in its mastery of soft robotics core technology and leading neurorehabilitation algorithms. The deep integration of software and hardware has created a biomimetic soft robot structure, which not only enhances flexibility and versatility but also significantly reduces the risk of secondary injuries potentially caused by traditional rigid robots, ensuring safe and effective rehabilitation.

At the same time, the multi-sensor fusion control algorithm ensures the precision and visualization of rehabilitation training, constructing a comprehensive rehabilitation pathway from limb stimulation to progress monitoring, accelerating the rehabilitation process, and enhancing treatment effectiveness. It adopts a modular design and assembly, with a short production cycle, compact size, and user-friendly operation.

In terms of product layout, Sirrem has launched three major series: the flagship medical version, professional rehabilitation version, and portable rehabilitation version, covering more than ten models with a wide price range from several thousand to hundreds of thousands of yuan. These products can meet full-scenario rehabilitation needs in hospitals, communities, and homes, helping patients seize the "golden period" of recovery.

2. ShineyoMedical Completes Nearly 100 Million Yuan in Series A+ Financing, Accelerating the Launch of Cardiac Electrophysiology and Peripheral Vascular Intervention Products.

ShineyoMedical, a provider specializing in cardiac electrophysiology and peripheral vascular interventional treatment solutions, recently announced the completion of nearly RMB 100 million in Series A+ financing. This round of financing was led by Guangzhou Jinkong Fund, with participation from multiple investment institutions including Zhuopu Capital, Jinxin Capital, and Zhangjiagang Industrial Capital. Existing shareholder Xingzheng Capital continued to provide support.

This round of funding will mainly be used for the construction of the company's commercialization team, acceleration of production base operations, and R&D of product pipelines, creating a differentiated design matrix of cardiac electrophysiology and peripheral vascular intervention products.

ShineyoMedical was established in May 2020 in the Zhangjiang High-Tech Zone of the China (Shanghai) Pilot Free Trade Zone. The company leverages three major technology research and development platforms: active devices, interventional catheters, and biomaterials, entering the two significant fields of cardiac electrophysiology and peripheral intervention. It aims to become a leading innovator-driven enterprise in electrophysiology and minimally invasive peripheral vascular interventional medical devices, providing doctors and patients with value-leading, affordable, innovative clinical solutions.

Since its establishment four years ago, ShineyoMedical has independently developed innovative products in cardiac electrophysiology and peripheral vascular intervention, such as the cardiac pulsed field ablation system (PFA) and venous closure system. The registration applications for these products were officially accepted by NMPA in the first half of 2024 and are expected to enter the commercial validation phase by the end of 2024.

3. Heartlight Bio completes multi-million yuan Pre-A+ round financing, accelerating the landing application of portable hemodialysis machines.

Following the Pre-A round of financing worth tens of millions of yuan in June, Shanghai Xinguang Biomedical Co., Ltd. ("Xinguang Bio"), which focuses on promoting the convenience of hemodialysis, announced the completion of a Pre-A+ round of financing worth several million yuan, exclusively invested by Leading Edge Ventures.

Sirrem's first independently developed product, a portable dialysis platform, is a pioneering innovation in China. It utilizes a unique dialysate regeneration technology that eliminates the need for complex water treatment systems. Weighing only 8 kilograms, the entire system reduces fixed investment costs by 70%. Its portability and rapid deployment make it highly advantageous for use in grassroots hospitals, homes, and during pandemics or wartime conditions.

Particularly noteworthy is that Xinguang Bio's portable dialysis machine abandons the traditional power method based on tubing and peristaltic pumps, instead adopting pneumatic diaphragm pump technology. This innovation not only significantly improves flow accuracy and reduces equipment costs but also greatly simplifies the operation process. The integration of consumables into a cartridge design enables fully automated device operation. Through different cartridge modules, the platform can provide various treatment functions such as hemodialysis, peritoneal dialysis, and CRRT. Operators simply need to insert the cartridge into the device to achieve one-touch operation, greatly reducing the professional requirements and learning costs for nurses.

4. China's ClearCorrect brand, Dr. Clear, completes billion-level Series A financing, exclusively invested by Qiming Venture Partners.

Recently, Changzhou Born Clear Aligner Intelligent Medical Technology Co., Ltd. ("Dr. Clear Aligner"), a Chinese invisible orthodontic brand, has completed a billion-yuan Series A financing round, exclusively invested by Qiming Venture Partners. The funds will be used for the research and development and construction of an automated production line for invisible aligners, product development based on biomechanics, AI intelligent solution software development, and market expansion both domestically and internationally.

Dr. Clear Aligner, established in 2016 with its headquarters in Shanghai, is a leading provider of early orthodontic solutions for children and invisible orthodontic solutions for adults, integrating production, academia, research, and sales. After eight years of development, Dr. Clear Aligner has gradually taken the lead in the flourishing invisible orthodontics market, leveraging its R&D advantages in both the early orthodontic treatment market for children and the adult orthodontics market.

Dr. Clear aligner, with big data model and artificial intelligence technology as the core, has launched a series of invisible orthodontic solutions in the course of development, producing more than a million invisible orthodontic appliances per year to serve doctors and orthodontic patients worldwide. In addition, the company has initiated in-depth cooperation with several domestic and international dental schools and research institutions to promote dental technology innovation and talent cultivation, and has collaborated with major dental medical institutions to jointly build a green ecosystem for the dental industry.

Since its establishment, Dr. Clear has been committed to providing users with scientific and precise orthodontic solutions through digital technology. The company continuously collaborates in-depth with orthodontic experts, universities, and research institutions both in China and internationally. In the field of early orthodontic treatment for children, it has proposed the concept of full-cycle orthodontic care for children and offers comprehensive orthodontic solutions covering all age groups. In the field of adult invisible orthodontics, the company has conducted in-depth research and development to introduce an alveolar arch coordinate system based on root-bone relationships, achieving complete and accurate data reconstruction along with innovative and correct mechanical algorithms, thereby promoting the high-quality development of orthodontic technology in China.

5. Addgene Completes Over Ten Million Yuan in Angel Round Financing, Accelerating the Application Process of Gene Editing Industry.

Guangzhou AddGene Technology Co., Ltd. (hereinafter referred to as "AddGENE"), announced the completion of an angel round of financing worth over ten million yuan, jointly invested by Yanghe Investment, Zhongda Venture Capital, and Qianhai Great Wall Fund. The funds raised from this round will be used to accelerate the company’s team building, enhance R&D capabilities, expand product portfolio, and develop overseas markets.

Addgene was founded in August 2017 and is located in the International Enterprise Incubator in Huangpu District, Guangzhou. The company was established by a returning doctorate with ten years of experience in gene editing technology and has accumulated extensive industry experience in CRISPR/Cas gene editing technology.

After years of technical research and development and accumulation, conducting fundamental technology research based on CRISPR/Cas technology, keeping up with international advanced technologies, and adhering to technological innovation, iGene has now established four core technology platforms: Editx™ Gene Editing, Bingo™ Point Mutation, LION™ Cell Targeted Integration, and FASST Rapid Nucleic Acid Detection, providing more comprehensive technical services for the ever-evolving gene editing research.

AddyGene persists in the research and development of fundamental technologies, modifying enzymes for gene editing based on three-dimensional structures, and obtaining enzyme preparations with performance far surpassing that of overseas well-known enterprises through self-developed preparation processes, gaining wide recognition from customers. The gene knockout kit developed using new transfection reagents can achieve rapid and scarless gene knockout in cells without toxicity to the cells, with an editing efficiency of 95% in THP-1 and other cells; it has launched the Bingo™ point mutation platform deeply optimized based on PE technology. The technical team has completed experiments in various hard-to-transfect cells, with an editing efficiency as high as 85%; the FASST nucleic acid rapid detection platform developed based on the CRISPR system can realize single-tube reaction, with a detection time of 20 minutes and a sensitivity of 10 copies.